SLV-154 Treatment of Advanced Cancers
This is a Phase 1 study comprising a Phase 1a dose-escalation portion and a Phase 1b expansion portion evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-154 across a range of dose levels when administered to subjects with advanced solid tumors.
Men or women (as appropriate for cancer type) of age ≥12 years. [+18]
Unstable malignancy involving the central nervous system. [+9]